瑞德西韦在肾移植受者合并COVID-19中的使用与安全性
该多中心队列研究纳入51例接受瑞德西韦治疗的肾移植受者合并COVID-19患者,评估结局与安全性。结果显示瑞德西韦耐受性良好,无因不良事件停药,未发现显著肝肾毒性或全身症状;但死亡率18.9%,≥65岁患者死亡率显著更高(45% vs. 3.2%)。
要点
- 瑞德西韦在肾移植受者中耐受性良好,无因不良事件停药。
- 未发现显著肝毒性或全身症状。
- 死亡率18.9%,≥65岁患者死亡率显著更高。
核心结论
- 在肾移植受者合并COVID-19的队列中,瑞德西韦在肾脏和肝脏毒性方面耐受性良好且安全,但需要随机试验评估其疗效。
研究设计与样本
- 多中心队列研究,纳入51例接受瑞德西韦治疗的肾移植受者合并COVID-19患者,评估结局与安全性。
主要发现
- 诊断时平均年龄60岁,距肾移植中位时间4.5年。
- 入院至使用瑞德西韦平均时间2天。
- 死亡率为18.9%,≥65岁患者死亡率显著更高(45% vs. 3.2%)。
- 急性肾损伤发生率为27.7%,但50%在治疗前已诊断。
临床怎么用
- 瑞德西韦可用于肾移植受者合并COVID-19的治疗,耐受性良好,但需监测肾功能和肝功能。
- 高龄(≥65岁)患者死亡率较高,需加强关注。
局限性
- 需要随机试验评估瑞德西韦的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. METHODS: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. RESULTS: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. CONCLUSION: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
引用
- Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, et al. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney Int Rep. 2021. PMID: 34250317. doi:10.1016/j.ekir.2021.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。